To mark World Haemophilia Day, we sit down with Professor Amit Nathwani of the UCL Cancer Institute to explore his journey to commercialising the groundbreaking haemophilia A treatment, Roctavian.
Host Nigel Campbell is joined by Prof Nathwani and Dr. Rick Fagan, UCLB Director of Biopharm, to explore how Amit’s work looking after patients with haemophilia in the NHS instilled a mission to develop a 'one and done' vaccine type approach to the condition.
Amit’s lab to market story, working with UCLB, led to the creation of Roctavian, a one-time gene therapy used for the treatment of adults with severe haemophilia A. The therapy, which was licensed to BioMarin Pharmaceutical Inc, received marketing approval in Europe in 2022 and US FDA approval in 2023, and is now available to patients commercially.
4
4/15/2024
A new treatment for people with haemophilia A, developed at UCL, is offering a new quality of life for people with the debilitating disease.
The technology was developed by Professor Amit Nathwani (UCL Cancer Institute and Institute of Immunity & Transplantation) and his team at UCL and St. Jude Children’s Research Hospital, USA.
It was licensed by UCL Business (UCLB), the commercialisation company for UCL, to BioMarin Pharmaceuticals Inc. in 2013.
Find out more in the case study on the UCL Innovation & Enterprise website.
62
4/12/2024
In this episode, Katy Bruce, CFO of UCL Business, and Charu Gorasia, CFO of UCL, will discuss the mutually beneficial relationship between the technology transfer office, such as UCLB, and the university. They will dive into the research income financial cycle and how the commercialisation income is distributed back into the research ecosystem. This podcast will also cover the challenges around commercialisation income, how to tackle these and what does the future hold
5
11/17/2023
In the tenth episode, Dr Anne Lane, CEO of UCLB and Dr Chris Hollowood, CEO of Syncona Investment Management, discussed the collaboration between their respective organisations in commercialising research. Syncona is a leading healthcare investment company focused on creating, building and scaling a portfolio of global leaders in life science; and Chris has been instrumental in the foundation and the development of its gene therapy strategy. In this podcast, Anne and Chris discussed how Syncona came about, its close relationship with UCL and UCL Business, and what attracted Syncona to invest in four UCLB companies. Chris also discussed the tech transfer ecosystem and what is next for Syncona.
6
10/17/2023
In the ninth episode of this podcast series, Ana Lemmo Charnalia, Senior Business Manager at UCLB, is in conversation with Orla O’Donnell , Divisional Manager at the UCL Div of Biosciences and former Chief Operating Officer of Health Digital CIC, a Community Interest Company incorporated in 2015 to commercialise HeLP-Diabetes. It is also an opportunity to celebrate Professor Elizabeth Murray’s life, who led the development of HeLP-Diabetes. Join them in this discussion about their experiences and learnings from an early-stage social venture to the national roll-out of an online programme for people with Type 2 diabetes.
1
9/14/2023
Ground-breaking research from UCL could mean new treatments for patients with cancers that have not responded to standard therapies.
The new therapies have evolved from research conducted by Dr Martin Pule and his team at the UCL Cancer Institute and NIHR University College London Hospitals Biomedical Research Centre.
The research was commercialised into a spinout company called Autolus in 2014. The spinout process was supported by UCL Business Ltd (UCLB), UCL's commercialisation company.
The company raised £30 million in investment from venture capital firm Syncona Partners. At the time this was one of the largest ever 'Series A' financing round for a European biotechnology company.
That was followed by 'Series B' funding of £40 million and 'Series C' funding of £59 million, before an IPO in 2018.
Find out how UCL spinouts solve complex global challenges and stimulate economic growth: https://ucl.ac.uk/enterprise
Find out more about UCLB: https://www.uclb.com
70
9/11/2023
In the third episode of this podcast series, UCLB Director of BioPharm, Dr Richard Fagan, is in conversation with UCL spinout Achilles Therapeutics’ (Achilles Tx) co-founder, Professor Charles Swanton. They will discuss Achilles Tx’s achievements and how TRACERx, the first study to track the evolution of cancer cells, will help us beat cancer.
2
3/8/2023
In the second episode of this podcast series, UCLB Senior Business Manager, Dr Mark Harding, explores UCL spinout Carbon Re's journey to market and their impact on reducing carbon emissions in heavy industries. He is joined by the co-founder and Chief Technology Officer of Carbon Re, Professor Aidan O'Sullivan.
7
2/8/2023